Skip to main content
. Author manuscript; available in PMC: 2021 Jul 9.
Published in final edited form as: Cancer Res. 2020 Jun 12;80(16):3399–3412. doi: 10.1158/0008-5472.CAN-19-3599

Figure 1. Maintenance of cancer cell binding, but significantly decreased direct cytotoxicity of 88hIgG1 compared to 88mIgG3 and parental hybridoma mAb, FG88.2.

Figure 1

Comparable HCT15 and COLO205 cell binding by 88hIgG1, 88mIgG3 and FG88.2 (hybridoma mAb)(A). Significantly reduced direct cytotoxicity (PI uptake) on HCT15 by 88hIgG1 compared to 88mIgG3 and FG88.2 (B). Significantly reduced proliferation inhibition by 88hIgG1 compared to 88mIgG3 and FG88.2 on COLO205 (C) and HCT15 (D). Significance (88hIgG1 compared to 88mIgG3) deduced from two-way ANOVA.